Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conditioning for Graft Failure After HSCT
NCT00617929Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2008
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of clofarabine in Graft failure, sponsored by Masonic Cancer Center. Primary endpoints: Rate of Sustained Donor Engraftment at 42 days and Overall Survival at 100 days. Started Jan 2008; status: terminated.
02
Drugs
clofarabine
03
Conditions
Graft failure
Beyond the preview
Go deeper on NCT00617929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617929.